Drugs / E-islet 01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07126873 | Aug 2025 → Dec 2027 expected | type 1 diabetes mellitus | EndoCell Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-islet 01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07126873 ↗ |
| Known as | Allogeneic Human E-islet | “Allogeneic Human E-islet (E-islet 01)” NCT07126873 ↗ |
| Modality | Cell therapy | “Allogeneic Human E-islet” NCT07126873 ↗ |
| Route | Other | “Infused into the hepatic portal vein” NCT07126873 ↗ |